Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370137 | 0.86 | DGAT1 (0.38) | DGAT1TYK2PDE4DCNR2MAPT | |
| SCHEMBL1369626 | 0.83 | PDE10A (0.41) | DGAT1TYK2CNR2 | |
| SCHEMBL14795206 | 0.83 | KLKB1 (0.36) | DGAT1MAPT | |
| SCHEMBL1370485 | 0.82 | TYK2 (0.33) | DGAT1TYK2PDE4DMAPT | |
| SCHEMBL1370704 | 0.82 | TYK2 (0.35) | DGAT1TYK2CNR2MAPT | |
| SCHEMBL1372031 | 0.82 | TYK2 (0.35) | DGAT1TYK2PDE4DCNR2MAPT | |
| SCHEMBL1370955 | 0.80 | TYK2 (0.34) | DGAT1TYK2CNR2 | |
| SCHEMBL1370792 | 0.79 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1370394 | 0.77 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL1371911 | 0.76 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | DGAT1 4772/4885TYK2 4/4885PDE4D 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.